
Sign up to save your podcasts
Or
For our first episode of 2022, we look into a new partnership between Perth-based oligonucleotides manufacturer SynGenis and Sydney-based diagnostic company SpeeDx. WA start-up SynGenis is the brainchild of Professor Rakesh Veedu, a world-renowned oligonucleotide chemical biologist. Sydney-based SpeeDx, led by CEO Colin Denver, is a privately owned company spun out of Johnson and Johnson that develops PCR testing solutions for infectious diseases including COVID-19. In the wake of the pandemic, SpeeDx faced a constrained supply of oligonucleotides which are a critical component of their diagnostic kits. MTPConnect brokered SpeeDx an introduction to SynGenis and the rest is history in the making!
5
11 ratings
For our first episode of 2022, we look into a new partnership between Perth-based oligonucleotides manufacturer SynGenis and Sydney-based diagnostic company SpeeDx. WA start-up SynGenis is the brainchild of Professor Rakesh Veedu, a world-renowned oligonucleotide chemical biologist. Sydney-based SpeeDx, led by CEO Colin Denver, is a privately owned company spun out of Johnson and Johnson that develops PCR testing solutions for infectious diseases including COVID-19. In the wake of the pandemic, SpeeDx faced a constrained supply of oligonucleotides which are a critical component of their diagnostic kits. MTPConnect brokered SpeeDx an introduction to SynGenis and the rest is history in the making!
52 Listeners
805 Listeners